Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2008, Vol. 13 ›› Issue (6): 716-720.
LIU Xiao-ping
Received:
2008-02-22
Revised:
2008-06-04
Published:
2020-10-14
CLC Number:
LIU Xiao-ping. Keap1-Nrf2-ARE signaling pathway in the chemoprevention of cancer[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2008, 13(6): 716-720.
[1] Anzenbacher P, Anzenbacherova E. Cytochromes P450 and metabolism of xenobiotics[J]. Cell Mol Life Sci, 2001, 58(5/6): 737-747. [2] Wilkinson JT, Clapper ML. Detoxication enzymes and chemoprevention[J]. Proc Soc Exp Biol Med, 1997, 216 (3): 192-200. [3] Itoh K, Ishii T, Wakabayashi N, et al. Regulatory mechanisms of cellar response to oxidative stress[J]. Free Radic Res, 1999, 31(4): 319-324. [4] Dhakshinamoorthy S, Long DJ 2nd, Jaiswal AK. Antioxidant regulation of genes encoding enzymes that detoxify xenobiotics and carcinogens[J]. Curr Top Cell Regul, 2000, 36:201-216. [5] Rushmore TH, Morton MR, Pickett CB. The antioxidant responsive element. Activation by oxidative stress and identification of the DNA consensus sequence required for functional activity[J]. J Biol Chem, 1991, 266(18): 11632-11639. [6] Kensler TW, Wakabayashi N, Biswal S. Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway[J]. Annu Rev Pharmacol Toxicol, 2007, 47 (2): 89-116. [7] Prestera T, Holtzclaw WD, Zhang Y, et al. Chemical and molecular regulation of enzymes that detoxify carcinogens [J]. Proc Natl Acad Sci USA, 1993, 90 (4): 2965-2969. [8] Tanigawa S, Fujii M, Hou DX. Action of Nrf2 and Keap1 in ARE-mediated NQO1 expression by quercetin[J]. Free Radic Biol Med, 2007, 42(11): 1690-1703. [9] Zhang Y, Gonzalez V, Xu MJ. Expression and regulation of glutathione S-transferase P1-1 in cultured human epidermal cells[J]. J Dermatol Sci, 2002, 30(3): 205-214. [10] Liu XP, Goldring CEP, Copple IM, et al. Extract of Ginkgo biloba induces the phase 2 genes through Keap1-Nrf2-ARE signalling pathway [J]. Life Sci, 2007, 80 (17): 1586-1591. [11] Nioi P, McHahon M, Itoh K, et al. Identification of a novel Nrf2-regulated antioxidant response element (ARE) in the mouse NAD(P) H:quinone oxidoreductase 1 gene: reassessment of the ARE consensus sequence[J]. Biochem J, 2003, 374(10): 337-348. [12] Li Y, Jaiswal AK. Regulation of human NAD(P) H: quinone oxidoreductase gene. Role of AP1 binding site contained within human antioxidant response element[J]. J Biol Chem, 1993, 268(28): 15097-15104. [13] Venugopal R, Jaiswal AK. Nrf1 and Nrf2 positively and c-Fos and Fra1 negatively regulate the human antioxidant response element-mediated expression of NAD(P) H: quinone oxidoreductase1 gene[J]. Proc Natl Acad Sci USA, 1996, 93(25): 14960-14965. [14] Wilkinson J, Radjendirane V, Pfeiffer GR, et al. Disruption of c-Fos leads to increased expression of NAD(P) H: quinine oxidoreductase1 and glutathione S-transferase[J]. Biochem Biophys Res Commun, 1998, 253(3): 855-858. [15] Nguyen T, Rushmore TH, Pickett CB. Transcriptional regulation of a rat liver glutathione S-transferase Ya subunit gene. Analy sis of the antioxidant response element and its activation by the phorbol ester 12-OtetradecanoylphorboL-13-acetate [J]. J Biol Chem, 1994, 269 (18): 13656-13662. [16] Talalay P, De Long MJ, Prochaska HJ. Identification of a common chemical signal regulating the induction of enzymes that protect against chemical carcinogenesis [J]. Proc Natl Acad Sci USA, 1988, 85(21): 8261-8265. [17] Itoh K, Chiba T, Takahashi S, et al. An Nrf2 smallMaf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements[J]. Biochem Biophys Res Commun, 1997, 236 (2): 313-322. [18] Yates MS, Kensler TW. Chemopreventive promise of targeting the Nrf2 pathway[J]. Drug News Perspect, 2007, 20(2): 109-117. [19] Satoh T, Okamoto SI, Cui J, et al. Activation of the Keap1 Nrf2 pathway for neuroprotection by electrophilic phase II inducers[J]. Proc Natl Acad Sci USA, 2006, 103(13): 768-773. [20] Moi P, Chan K, Asunis I, et al. Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2 AP1 repeat of the h-globin locus control region[J]. Proc Natl Acad Sci USA, 1994, 91(21): 9926-9930. [21] Chan K, Lu R, Chang JC, et al. NRF2, a member of the NFE2 family of transcription factors, is not essential for murine erythropoiesis, growth, and development[J]. Proc Natl Acad Sci USA, 1996, 93(24): 13943-13948. [22] Ramos-GomezM, Kwak M, Dolan PM, et al. Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice[J]. Proc Natl Acad Sci USA, 2001, 98(6): 3410-3415. [23] Ramos-Gomez M, Dolan PM, Itoh K, et al. Interactive effects of nrf2 genotype and oltipraz on benzo[a] pyrene-DNA adducts and tumor yield in mice[J]. Carcinogenesis, 2003, 24(3): 461-467. [24] Fahey JW, Haristoy X, Dolan PM, et al. Sulforaphane inhibits extracellular, intracellular, and antibiotic-resistant strains of Helicobacter pylori and prevents benzo[a] pyrene-induced stomach tumors[J]. Proc Natl Acad Sci USA, 2002, 99(11): 7610-7615. [25] Kwak MK, Egner PA, Dolan PM, et al. Role of phase 2 enzyme induction in chemoprotection by dithiolethiones [J]. Mutat Res, 2001, 480/481(Sep 1): 305-315. [26] Chan K, Han XD, KanW. An important function of Nrf2 in combating oxidative stress: detoxification of acetaminophen[J]. Proc Natl Acad Sci USA, 2001, 98(8): 4611-4616. [27] Cho HY, Jedlicka AE, Reddy SPM, et al. Role of NRF2 in protection against hyperoxic lung injury in mice[J]. Cell Mol Biol, 2002, 26(2): 175-182. [28] Chan JY, Kwong M. Impaired expression of glutathione synthetic enzyme genes in mice with targeted deletion of the Nrf2 basic-leucine zipper protein[J]. Biochim Biophys Acta, 2000, 1517(1): 19-26. [29] Kwak MK, Itoh K, Yamamoto M, et al. Enhanced expression of the transcription factor Nrf2 by cancer chemopreventive agents:role of antioxidant response elementlike sequences in the nrf2 promoter[J]. Mol Cell Biol, 2002, 22(4): 2883-2892. [30] McMahonM, Itoh K, Yamamoto M, et al. Keap1-dependent proteasomal degradation of transcription factor nrf2 contributes to the negative regulation of antioxidant response element-driven gene expression[J]. J Biol Chem, 2003, 278(24): 21592-21600. [31] Itoh K, Wakabayashi N, Katoh Y, et al. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain [J]. Genes Dev, 1999, 13(1): 76-86. [32] Dinkova-Kostova AT, Holtzclaw WD, Cole RN, et al. Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants[J]. Proc Natl Acad Sci USA, 2002, 99(18): 11908-11913. [33] Xue FL, Cooley L. Kelch encodes a component of intercellular bridges in Drosophila egg chambers[J]. Cell, 1993, 72(5): 681-693. [34] Hong F, Freeman ML, Liebler DC. Identification of sensor cysteines in human Keap1 modified by the cancer chemopreventive agent sulforaphane[J]. Chem Res Toxicol, 2005, 18(12): 1917-1926. [35] Li W, JainMR, Chen C, et al. Nrf2 Possesses a redoxinsensitive nuclear export signal overlapping with the leucine zipper motif[J]. J Biol Chem, 2005, 280(31): 28430-28438. [36] Kang MI, Kobayashi A, Wakabayashi N, et al. Scaffolding of Keap1 to the actin cytoskeleton controls the function of Nrf2 as key regulator of cytoprotective phase 2 genes [J]. Proc Natl Acad Sci USA, 2004, 101 (7): 2046-2051. [37] Stewart D, Killeen E, Naquin R, et al. Degradation of transcription factor Nrf2 via the ubiquitin-proteasome pathway and stabilization by cadmium[J]. J Biol Chem, 2003, 278(4): 2396-2402. [38] Nguyen T, Sherratt PJ, Huang HC, et al. Increased protein stability as a mechanism that enhances Nrf2-mediated transcriptional activation of the antioxidant response element. Degradation of Nrf2 by the 26 S proteasome[J]. J Biol Chem, 2003, 278(7): 4536-4541. [39] Pahl HL, Baeuerle A. Control of gene expression by proteolysis[J]. Curr Opin Cell Biol, 1996, 8(3): 340-347. [40] Dinkova-Kostova AT, Holtzclaw WD, Wakabayashi N. Keap1, the sensor for electrophiles and oxidants that regulates the phase 2 response, is a zinc metalloprotein[J]. Biochemistry, 2005, 44(18): 6889-6899. |
[1] | YOU Rongli, HUANG Yurong, MAORui, HAI Lina, WANG Yingli, WANG Yan. Mechanism of compound kushen injection in the treatment of lung cancer based on serum metabolomics and network pharmacology [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 988-999. |
[2] | HE Lihua, ZHU Xiuzhi, JIANG Yizhou. Research progress on immunotherapy for triple-negative breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 842-853. |
[3] | ZHANG Huyunlong, ZHU Xiuzhi, JIN Xi, SHAO Zhimin. Mechanisms of endocrine-resistance and therapeutic breakthroughs in hormone receptor-positive, HER2-negative breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 854-865. |
[4] | FU Xiaoyu, KONG Deguang, LI Juanjuan. Treatment progress of triple positive breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 866-875. |
[5] | LUO Shiping, ZHANG Jie, YU Yushuai, SONG Chuangui. Advances in targeted therapy for HER2-positive breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 876-886. |
[6] | XIANG Yimei, ZHANG Ningning, HUANG Yuxin, ZENG Xiaohua. Research progress of biomarkers related to the efficacy of HER2 positive breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 887-897. |
[7] | CHEN Keyu, HUANG Yuan, WANG Xiaojia, ZHENG Yabing. Clinical application and research progress of antibody drugs conjugation in breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 898-909. |
[8] | LI Mengxi, ZHANG Kejing, XIA Fan. Research progress in vaccine for breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 918-925. |
[9] | HOU Qiong, LIU Fei, CHEN Chuanrong. Immunotherapy combined with anti-angiogenic drugs and chemotherapy in negative driver gene and advanced non-small cell lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 775-779. |
[10] | ZHANG Jinghui, WEI Haoliang, WANG Li, LI Jingkai, ZHANG Baolai, YANG Xiaolai. Effects of AMI-1 on the activity of pancreatic cancer cells in vitro by down-regulating PRMT5 expression [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 601-608. |
[11] | FU Ting, LI Fang, PAN Dayan, XIA Yuanyuan, ZHANG Qiuyuan. miR-718 from exosomes of lung cancer cells induces angiogenesis by targeting PTEN [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 624-632. |
[12] | WANG Yan, ZHANG Jinhui, ZHAO Yongchen, LIU Hongxiang, LIU Yawei, MIAO Huanhuan, YANG Xincai. Sequoiaflavone inhibits stem cell properties such as proliferation and invasion of gastric cancer cells by down-regulating PI3K/AKT signaling pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 508-513. |
[13] | FENG Zhuangzhuang, SONG Ruiping, DOU Pengcheng, CHEN Xinyi, ZUO Jiaojiao, SHU Jin. Effect of Zhiwei Fuwei Pills on autophagy in gastric antrum tissue of rats with precancerous lesions of gastric cancer based on mTOR/Beclin1/LC3 signaling axis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 361-370. |
[14] | SHI Dawei, ZHENG Xiaoyong, JIN Xiaodan, ZHAO Xiaoman, CHEN Jie, DU Xingjun. Implication of XPC rs2228001 polymorphism on the prognosis of patients with colorectal cancer who were treated with capecitabine-based adjuvant chemotherapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 391-399. |
[15] | WEI Zhenzhen, SUI Hua, JIANG Yulang, SUN Mingyu, YAN Huaru, WANG Ziyuan. Research on the molecular mechanism of Zuo Jin Wan combined with cetuximab inducing ferroptosis in KRAS mutant colorectal cancer cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 130-137. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||